Shenbai Granules
PreclinicalSmall molecule
Shenbai Granules is one of 10 small molecule programs targeting Colorectal Adenoma. It is currently in Preclinical.
1
Indications
3
Total Trials
2
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Colorectal Adenoma
#DrugCompanyPhaseTrials
1Linzess
AbbVieApproved
Lialda
TakedaApproved
Bayer Aspirin
BayerPhase 3
Celebrex
PPhiladelphia Eye Associates
Phase 2
Glucophage
Boehringer IngelheimPhase 2
Berberine Hydrochloride
XXijing Hospital of Digestive Diseases
Phase 3
Mesalazine
FerringPhase 2
Acetylsalicylic Acid Lysinate
MMedical University of Vienna
Phase 3
Berberine
XXijing Hospital of Digestive Diseases
Phase 2
Shenbai Granules
JJiangsu Famous Medical Technology Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Shenbai Granules. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details